CrossrefInfokarte
Clinical Utility of [18F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy
Clinical Breast Cancer · 2026-11 · 26 (11) · 32-39
DOI: 10.1016/j.clbc.2026.09.008 ↗Abstract
Kein Abstract verfügbar.
EUVIMED